RT @uptoTate: Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c
Tweet Content
Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
Links
Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Paramete…
http://ow.ly/vESX50Lz2Wy
Show on Archive Page
On
Display in Search Results
On
PDQ
Off